Meeting
2019 ASCO Annual Meeting
A phase II, open label, multicenter trial of avelumab in patients with advanced, metastatic high-grade neuroendocrine carcinomas NEC G3 (WHO 2010) progressive after first-line chemotherapy (AVENEC).
Authors
Christian Fottner
I. Medical Department, Mainz University Medical Center, Mainz, Germany
Christian Fottner , Leonidas Apostolidis , Martina Ferrata , Sebastian Krug , Patrick Michl , Arno Schad , Wilfried Roth , Dirk Jaeger , Peter R. Galle , Matthias M. Weber
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Neuroendocrine/Carcinoid
Clinical Trial Registration Number
NCT03352934
Citation
J Clin Oncol 37, 2019 (suppl; abstr 4103)
DOI
10.1200/JCO.2019.37.15_suppl.4103
Abstract #
4103
Poster Bd #
208
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
SOGUG-vexillum: Phase II non-randomized clinical trial of nivolumab/ipilimumab maintenance following first-line chemotherapy in unresectable locally advanced or metastatic urothelial cancer.
First Author: Guillermo de Velasco
Poster
2019 ASCO Annual Meeting
Apatinib for locoregionally recurrent or metastatic nasopharyngeal carcinoma after failure of first-line chemotherapy: A multicenter, phase II trial.
First Author: Wei Jiang
Poster
2022 ASCO Annual Meeting
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1L chemotherapy.
First Author: Begoña Pérez-Valderrama